Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 08 - 03 entities : Sanofi save search
BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance
Published: 2022-08-03 (Crawled : 20:00) - investors.biomarin.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.7%
H: 4.68%
C: 3.43%
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
Published: 2022-08-03 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
covid-19 sales eylea drop antibody dupixent
Drug Pricing Debates Heat Up Just in Time for Election Season
Published: 2022-08-03 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.64%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
drug
As Healthcare Crises Pile Up, Pharma Struggles to Meet Demand
Published: 2022-08-03 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
pharma
PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer
Published: 2022-08-03 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 1.38%
H: 1.07%
C: 0.44%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
IMTX | $10.19 -0.68% -0.69% 180K
|
Health Technology
|
| O: 4.93%
H: 0.0%
C: -3.61%
EDIT | $5.5 -0.9% -0.91% 2.3M
|
Health Technology
|
| O: 6.43%
H: 10.6%
C: 6.56%
results
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 47.44%
H: 0.0%
C: 0.0%
topline positive results study
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Published: 2022-08-03 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
libtayo antibody cancer prostate cancer pd-1 inhibitor
U.S. Small-Molecule APIs Market to Reach $7.84 Billion by 2027
Published: 2022-08-03 (Crawled : 11:00) - prnewswire.com
LZAGF | $563.5 -19.1% 6
|
Health Technology
|
| O: -3.53%
H: 0.0%
C: 0.0%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.8%
H: 0.2%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
LZAGY | $55.65 0.02% 32K
|
Professional, Scientific, and T...
|
| O: 0.55%
H: 0.48%
C: 0.36%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.71%
H: 1.52%
C: 0.71%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.11%
H: 0.31%
C: -0.34%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.64%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.29%
H: 0.24%
C: -0.58%
ALB | $112.15 0.31% -0.13% 2M
|
Process Industries
|
| O: 0.87%
H: 0.0%
C: -2.63%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
market
Regeneron Reports Second Quarter 2022 Financial and Operating Results
Published: 2022-08-03 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
results
Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 04:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.8%
H: 0.2%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
NPCE S | $13.78 -1.57% -1.6% 96K
|
Manufacturing
|
| O: 0.52%
H: 3.71%
C: -2.93%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.11%
H: 0.31%
C: -0.34%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.29%
H: 0.24%
C: -0.58%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.41%
H: 3.35%
C: 1.71%
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: 2.47%
H: 2.8%
C: -2.67%
approval therapeutics growth market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.